摘要
Branislav LUKIC 医师
医学博士
Exosomes and Energy-Based Devices: Synergy in Regeneration and Complication Management
Objectives: Explain molecular mechanisms of exosome action in skin regeneration.
Evaluate clinical applications in pigmentation, scars, and recovery.
Integrate exosomes with EBDs and injectables to enhance outcomes and reduce complications.
Introduction: Exosomes are extracellular vesicles carrying proteins, growth factors, and miRNAs that regulate fibroblasts, angiogenesis, and immune responses. They are emerging as potent tools in regenerative aesthetics, with applications in pigmentation, scars, and post-device recovery.
We review mechanisms of fibroblast activation, angiogenesis, and immune modulation. Case vignettes highlight exosome use with lasers, peels, and injectables for pigmentation, scars, and complication rescue. Preclinical and early clinical data on wound healing and scar revision are included.
Materials / method: Patients with acne scars, pigmentation disorders, and delayed recovery post-laser were treated (Fitzpatrick I–IV).
Protocol: an energy-based device session (fractional laser, IPL, or Nd:YAG depending on indication), followed by microneedling at controlled depth.
Immediately post-microneedling, purified exosomes were applied and driven into the dermis through microchannels.
Sessions were repeated at intervals (every 4–6 weeks), combined with supportive cosmeceuticals and strict photoprotection.
https://doi.org/10.1093/burnst/tkae047
https://doi.org/10.1093/asj/sjab125
Results: Exosome protocols demonstrate faster re-epithelialization, reduced inflammation, improved angiogenesis, and normalized pigmentation compared with device monotherapy. Clinical reports show fewer complications, quicker recovery, and superior patient-reported outcomes in pigmentation and scar cases.
Conclusion: Exosomes function as amplifiers and safeguards in regenerative aesthetics. When integrated with energy-based devices or injectables, they accelerate healing, reduce complications, and enhance results. Standardization in sourcing, dosing, and protocols will be key for broad clinical adoption.
披露 - Branislav LUKIC
> 您是否获得了任何资金来支持您关于这个主题的研究?
不是
> 您在这项研究工作中是否获得过任何酬金、报酬或其他形式的补偿?
不是
> 您是否与任何可能与您研究中涉及的药物、材料或器械存在激烈竞争的实体有任何财务关系?
不是
> 您是否拥有或已申请过与您研究中所讨论的仪器、药物或材料相关的任何专利?
不是
这项工作没有任何直接或间接的资金支持。由作者自己承担责任。
Published on 2026年 4月 28日 - Recorded during IMCAS World Congress 2026